Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EA3202 | ECOG-ACRIN | A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA3211 | ECOG-ACRIN | Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA3231 | ECOG-ACRIN | A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA4151 | ECOG-ACRIN | A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA4181 | ECOG-ACRIN | A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA4232 | ECOG-ACRIN | A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5123 | ECOG-ACRIN | Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC | Adult CIRB - Late Phase Emphasis | Completed | |
| EA5142 | ECOG-ACRIN | Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5152 | ECOG-ACRIN | A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5161 | ECOG-ACRIN | Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) | Adult CIRB - Late Phase Emphasis | Available to Open |